Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses
about
Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility.Characterization of a highly replicative intergroup M/O human immunodeficiency virus type 1 recombinant isolated from a Cameroonian patient.Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa.Non-M variants of human immunodeficiency virus type 1.Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational featuresPerformance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from UgandaQuantitation of human immunodeficiency virus type 1 group O load in plasma by measuring reverse transcriptase activityBaseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.HIV Genetic Diversity and Drug Resistance.A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.A new real-time quantitative PCR for diagnosis and monitoring of HIV-1 group O infection.Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.Virus subtype-specific features of natural simian immunodeficiency virus SIVsmm infection in sooty mangabeysThe Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs.Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France.HIV-1 group O infection in Cameroon from 2006 to 2013: Prevalence, genetic diversity, evolution and public health challenges.Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria.Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B.Retrospective analysis of the HIV-1 reverse transcriptase inhibitors' resistance in Silesia, PolandNeuroAIDS in AfricaA Multiplex PCR Approach for Detecting Dual Infections and Recombinants Involving Major HIV VariantsThe Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.The challenge of HIV-1 subtype diversity.Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to preventionVirological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.Census and analysis of persistent false-negative results in serological diagnosis of human immunodeficiency virus type 1 group O infections.Multiple HIV-1/M + HIV-1/O dual infections and new HIV-1/MO inter-group recombinant forms detected in Cameroon.Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients.Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG.Novel Time-Resolved Fluorescence Europium Nanoparticle Immunoassay for Detection of Human Immunodeficiency Virus-1 Group O Viruses Using Microplate and Microchip Platforms.HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.
P2860
Q28379463-E856889A-8ED7-4FE6-A9CF-74E864E4A946Q30322838-FD385AA9-A355-45B1-A647-89589CE42A4DQ30327384-21C95D81-975C-4F49-96ED-75189F4059CEQ30432689-DA8A55ED-BE87-46F5-8CA9-F37799D0910BQ33785338-2001E11D-7699-42FB-8894-338C17C3603DQ33906239-1E44398E-DFEA-45BD-8ACC-D09E894ECD2DQ33951471-3D9FAC1B-889E-4DAD-BAD1-9FD2DF87DBE3Q33974239-0C932690-A786-4A59-8163-25C69531855AQ33974930-121D52EC-9B4F-466C-8592-D8706EE3F775Q34108713-3B5FCD2F-BC92-4638-840E-872646B7B216Q34110204-67199F03-1FDA-4B80-A443-731D8627D039Q34120878-A0C78BC5-8380-4C6D-9F97-5F137FF2689CQ34303603-BF688AC7-5BB9-408E-BCA0-4ECA68A67724Q34437450-BCC1D6E7-9035-4BD3-8128-A81AF33077DCQ35260403-DCDCF38C-02E9-464D-9DA6-41EE675586F8Q35260590-E4FD19FF-03D9-4AF9-AE0B-D61A973DA3F6Q35742512-7A5FC2F8-ECF0-4CE8-B482-AD843556F2FDQ35807096-C6A4AB60-C46F-41DC-B47D-EF009EBE51E2Q35857522-851379EB-CE6E-43A9-BCDB-732D46EEC0ADQ35947635-140357FF-E00E-41AC-8ABA-2A0D23F1B430Q36077418-395BC914-3B05-48B8-A084-80948C1BDE73Q36099119-3127D0A0-145A-4D1C-8A53-76C05112C166Q36239954-66DFAACF-0928-4BCB-B4FC-E463EA92EEE7Q36376394-B1840E84-98C1-4C31-BD02-0A0F4147F7A2Q36418462-1373D71B-A007-40B1-BF76-9CD1EA151BA6Q36423642-6A9169EC-E7F7-4041-B1C0-C8052435CFBEQ36473782-40F7B60F-C7C3-43D9-83DE-1678609B5E90Q36547128-A37316F2-3257-4CAF-B648-E394884EDA9AQ36834771-7530E279-45AA-4CFA-ABA3-40D773A91D13Q37018369-D10E3195-1FDD-4E64-AECB-E6A23D13707CQ37038453-325BA7ED-333E-46CE-94A1-CB231B1D0C5FQ37071435-320648AB-1EF6-4C09-BC8C-D5389908055FQ37256366-B7AC68BA-AC4D-4AC6-BE32-F027338AC5C0Q37333651-BFBBF523-3E8E-4029-8352-BF8ACC1350E6Q37586704-5B6C3259-2CAE-49A2-81DE-F4DA9AC8B27AQ37730522-0E35A127-C9A6-4B62-B60E-7FC1942BF3BCQ39461924-4C1ABA83-89EB-4A44-AE1D-A5C9F2A98143Q39626666-88DF8645-3509-4670-B037-5A1B50F44B24Q39919619-A27AD51A-98DF-4159-9B56-E2F2B83D25FDQ40797960-47A664A6-E880-4DC2-BA02-59F60006A459
P2860
Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses
description
1997 nî lūn-bûn
@nan
1997 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Susceptibility of human immuno ...... notypic and genotypic analyses
@ast
Susceptibility of human immuno ...... notypic and genotypic analyses
@en
Susceptibility of human immuno ...... notypic and genotypic analyses
@nl
type
label
Susceptibility of human immuno ...... notypic and genotypic analyses
@ast
Susceptibility of human immuno ...... notypic and genotypic analyses
@en
Susceptibility of human immuno ...... notypic and genotypic analyses
@nl
prefLabel
Susceptibility of human immuno ...... notypic and genotypic analyses
@ast
Susceptibility of human immuno ...... notypic and genotypic analyses
@en
Susceptibility of human immuno ...... notypic and genotypic analyses
@nl
P2093
P2860
P1433
P1476
Susceptibility of human immuno ...... notypic and genotypic analyses
@en
P2093
D Descamps
F Brun-Vézinet
F Letourneur
I Loussert-Ajaka
S Saragosti
P2860
P304
P407
P577
1997-11-01T00:00:00Z